tiprankstipranks
Akero Therapeutics Advances in MASH Treatment Trials
PremiumCompany AnnouncementsAkero Therapeutics Advances in MASH Treatment Trials
2M ago
Is AKRO a Buy, Before Earnings?
Premium
Pre-Earnings
Is AKRO a Buy, Before Earnings?
2M ago
Akero Therapeutics reports Q3 EPS ($1.05), consensus (90c)
Premium
The Fly
Akero Therapeutics reports Q3 EPS ($1.05), consensus (90c)
3M ago
Akero Therapeutics reports Q2 EPS (81c), consensus (90c)
PremiumThe FlyAkero Therapeutics reports Q2 EPS (81c), consensus (90c)
6M ago
Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial
Premium
The Fly
Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial
8M ago
Akero Therapeutics initiated with an Outperform at Wolfe Research
Premium
The Fly
Akero Therapeutics initiated with an Outperform at Wolfe Research
8M ago
Akero Therapeutics files automatic mixed securities shelf
PremiumThe FlyAkero Therapeutics files automatic mixed securities shelf
9M ago
Akero Therapeutics reports Q1 EPS (90c), consensus (95c)
Premium
The Fly
Akero Therapeutics reports Q1 EPS (90c), consensus (95c)
9M ago
Akero Therapeutics appoints Gangloff as Chief Technology Officer
Premium
The Fly
Akero Therapeutics appoints Gangloff as Chief Technology Officer
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100